LMR Partners’s Co-Diagnostics CODX Stock Holding History

LMR Partners’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-462	Closed	-$114K	–	1026
2021 Q2	$114K	Buy	+462	New	+$119K	﹤0.01%	843

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $309M AUM 22.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LMR Partners's CODX Position: Q3 2021 in Review

LMR Partners sold out of Co-Diagnostics (CODX) in Q3 2021, closing a stake of 462 shares — an estimated $114K sold.

LMR Partners first reported a position in CODX in Q2 2021 and held it in 1 quarter. The position peaked at $114K in Q2 2021. 78 funds tracked by Wall St. Rank hold CODX as of Q3 2021.

LMR Partners reported no remaining Co-Diagnostics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 462 Co-Diagnostics shares in Q3 2021, an estimated $114K.
LMR Partners first reported a position in Co-Diagnostics in Q2 2021 and held it in 1 quarter.
LMR Partners's Co-Diagnostics position peaked at $114K in Q2 2021.
78 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.